Yuichi Ando
YOU?
Author Swipe
View article: Efficacy and safety of immune checkpoint inhibitor rechallenge following immune-related adverse events: a review
Efficacy and safety of immune checkpoint inhibitor rechallenge following immune-related adverse events: a review Open
Immune checkpoint inhibitors (ICIs), which target immune regulatory molecules such as cytotoxic T-lymphocyte–associated protein 4 and programmed death-ligand 1, are widely used as standard treatments for various cancer types. However, by o…
View article: Correction: Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma
Correction: Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma Open
[This corrects the article DOI: 10.1371/journal.pone.0307580.].
View article: Fever Following Treatment with Atezolizumab Plus Bevacizumab Predicts Liver Injury in Patients with Unresectable Hepatocellular Carcinoma: A Prospective Observational Analysis
Fever Following Treatment with Atezolizumab Plus Bevacizumab Predicts Liver Injury in Patients with Unresectable Hepatocellular Carcinoma: A Prospective Observational Analysis Open
Introduction: Liver injury is a treatment-related adverse event (liver-TRAE), one of the most common complications of atezolizumab plus bevacizumab (Atez/Bev) therapy, when treating unresectable hepatocellular carcinoma (uHCC). Fever follo…
View article: Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events
Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events Open
Background While immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, they can trigger severe immune-related adverse events (irAEs). The safety and efficacy of ICI retreatment after severe irAEs remain poorly understoo…
View article: Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast
Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast Open
Background High tumor mutational burden (TMB-H) is an established biomarker for a favorable response to immune checkpoint inhibitors. However, tumor mutational burden (TMB) in invasive ductal carcinoma (IDC) and invasive lobular carcinoma …
View article: Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast
Tumor mutational burden status and clinical characteristics of invasive lobular carcinoma of the breast Open
Background High tumor mutational burden (TMB-H) is an established biomarker for a favorable response to immune checkpoint inhibitors. However, tumor mutational burden (TMB) in invasive ductal carcinoma (IDC) and invasive lobular carcinoma …
View article: Clinical characteristics of immune checkpoint inhibitor-related pancreatic injury with pancreatitis in patients with advanced malignancies
Clinical characteristics of immune checkpoint inhibitor-related pancreatic injury with pancreatitis in patients with advanced malignancies Open
ICI-PI with pancreatitis is rare but has become more prevalent with the increasing use of ICIs. Future prospective multicenter studies are needed to confirm these findings and develop standardized diagnostic and treatment protocols.
View article: Genomic profiles of patients with skin melanoma in the era of immune checkpoint inhibitors
Genomic profiles of patients with skin melanoma in the era of immune checkpoint inhibitors Open
The use of immune checkpoint inhibitors (ICIs) for treating melanoma has dramatically improved patient prognosis. The genomic profiles of patients receiving ICI therapy would provide valuable information for disease management and treatmen…
View article: Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma
Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma Open
Background This study aimed to identify the associations between individual KRAS , STK11 , KEAP1 , or TP53 mutations, as well as the comutation status of these genes, and the tumor mutation burden (TMB) with clinical outcomes of lung adeno…
View article: Efficacy of Magnesium Supplementation in Cancer Patients Developing Hypomagnesemia Due to Anti-EGFR Antibody: A Systematic Review
Efficacy of Magnesium Supplementation in Cancer Patients Developing Hypomagnesemia Due to Anti-EGFR Antibody: A Systematic Review Open
Background/Aim: Hypomagnesemia is a common side effect of anti-epidermal growth factor receptor (EGFR) antibodies, which may lead to arrhythmia. However, there are no evidence-based guidelines for magnesium (Mg) supplementation in the mana…
View article: Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non‐small‐Cell Lung Cancer in Patients Aged 75 Years and Older
Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non‐small‐Cell Lung Cancer in Patients Aged 75 Years and Older Open
Pembrolizumab is a major treatment for recurrent or advanced non‐small‐cell lung cancer (NSCLC). However, data on its use and pharmacokinetics (PK) in older patients are limited. This open‐label, multicenter, observational study evaluated …
View article: Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer.
Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer. Open
In Japan, systemic chemotherapy is the standard treatment for unresectable, advanced, or recurrent gastric cancer. However, numerous patients with gastric cancer do not receive late-line treatment because of the rapid progression of gastri…
View article: Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors Open
Although immune checkpoint inhibitors have greatly improved cancer therapy, they also cause immune-related adverse events, including a wide range of inflammatory side effects resulting from excessive immune activation. Types of immune-rela…
View article: Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer
Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer Open
Purpose A high risk of febrile neutropenia (FN) from neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) for esophageal cancer has been reported. The optimal timing of prophylactic use of pegfilgrastim remains to be …
View article: Low Expectancy of Conversion Surgery with R0 Resection in Patients with CEA > 5.0 ng/mL at the Initial RECIST Evaluation for Metastatic Gastric Cancer
Low Expectancy of Conversion Surgery with R0 Resection in Patients with CEA > 5.0 ng/mL at the Initial RECIST Evaluation for Metastatic Gastric Cancer Open
This retrospective study examined early the predictive factors for successful conversion surgery (CS) with R0 resection in patients with metastatic gastric cancer (MGC) who underwent systemic chemotherapy. This study included 204 patients …
View article: Supplementary Figure S4 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Supplementary Figure S4 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors Open
Supplementary Figure S4. Exposure-response analysis of Cmax on C1-D1 vs. best response in LGG subjects.
View article: Supplementary Figure S3 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Supplementary Figure S3 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors Open
Supplementary Figure S3. Maximum change from baseline in the sum of target lesions and treatment duration ("other tumor types", intrahepatic cholangiocarcinoma, glioblastoma).
View article: Supplementary Table S12 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Supplementary Table S12 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors Open
Supplementary Table S12. NGS analysis of select tumor-associated genes in archival tumor tissue obtained from a subset of subjects.
View article: Supplementary Figure S1 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Supplementary Figure S1 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors Open
Supplementary Figure S1. Geometric mean plasma concentration-time profiles of BAY1436032 at dose levels of 150 mg to 1500 mg.
View article: Supplementary Table S12 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Supplementary Table S12 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors Open
Supplementary Table S12. NGS analysis of select tumor-associated genes in archival tumor tissue obtained from a subset of subjects.
View article: Supplementary Figure S2 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Supplementary Figure S2 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors Open
Supplementary Figure S2. Tumor scans.
View article: Data from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Data from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors Open
Purpose:BAY1436032, an inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), was active against multiple IDH1-R132X solid tumors in preclinical models. This first-in-human study was designed to determine the safety and pharmacokinetics o…
View article: Supplementary Data from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Supplementary Data from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors Open
Supplementary Methods, Supplementary Results, Supplementary Tables S1-S11
View article: Supplementary Figure S2 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Supplementary Figure S2 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors Open
Supplementary Figure S2. Tumor scans.
View article: Supplementary Figure S1 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Supplementary Figure S1 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors Open
Supplementary Figure S1. Geometric mean plasma concentration-time profiles of BAY1436032 at dose levels of 150 mg to 1500 mg.
View article: Supplementary Figure S4 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Supplementary Figure S4 from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors Open
Supplementary Figure S4. Exposure-response analysis of Cmax on C1-D1 vs. best response in LGG subjects.
View article: Supplementary Data from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Supplementary Data from Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors Open
Supplementary Methods, Supplementary Results, Supplementary Tables S1-S11